Myosin heavy chain isoform expression: Influence on isointertial and isometric performance

This is the publisher's version, also found at http://ehis.ebscohost.com/ehost/detail?vid=3&sid=c184ec76-77d8-4a98-bb1f-f5bceba902aa%40sessionmgr10&hid=2&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#db=s3h&AN=19495568Thirty-six healthy men with varying degrees of physical training background performed maximal-effort isometric and isoinertial knee extensor actions, with relative loads equal to 40% and 70% of one-repetition maximum. Force, velocity, and power were derived from force and linear position transducers at 500 Hz. Biopsies were taken from the vastus lateralis and analyzed by SDS-PAGE for relative myosin heavy chain (MHC) content. Relative MHC IIx content was included in a regression model, and explained variance noted. Relative MHC I content was subsequently added to the regression model to determine what, if any, additional variance was explained beyond that of MHC IIx. Results indicated that no relationship ( r = 0.0 to 0.1) exists between the relative expression of MHC isoforms from the vastus lateralis and isometric/isoinertial performance in a population with diverse training backgrounds. Lack of nervous system adaptations in the untrained subjects in the study possibly attenuates the significant relationship between MHC and in-vivo muscle performance previously established in trained populations. ABSTRACT FROM AUTHO

Measurement of resistance exercise force expression

This is the publisher's version, also found at http://ehis.ebscohost.com/ehost/detail?sid=afef5b5e-42ad-4a92-896e-f02e050a2011%40sessionmgr10&vid=1&hid=17&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#db=s3h&AN=13021242Displacement-based measurement systems are becoming increasingly popular for assessment of force expression variables during resistance exercise. Typically a linear position transducer (LPT) is attached to the barbell to measure displacement and a double differentiation technique is used to determine acceleration. Force is calculated as the product of mass and acceleration. Despite the apparent utility of these devices, validity data are scarce. To determine whether LPT can accurately estimate vertical ground reaction forces, two men and four women with moderate to extensive resistance training experience performed concentric-only (CJS) and rebound (RJS) jump squats, two sessions of each type in random order. CJS or RJS were performed with 30%, 50%, and 70% one-repetition maximum parallel back squat 5 minutes following a warm-up and again after a 10-min rest. Displacement was measured via LPT and acceleration was calculated using the finite-difference technique. Force was estimated from the weight of the lifter-barbell system and propulsion force from the lifter-barbell system. Vertical ground reaction force was directly measured with a single-component force platform. Two-way random average- measure intraclass correlations (ICC) were used to assess the reliability of obtained measures and compare the measurements obtained via each method. High reliability (ICC > 0.70) was found for all CJS variables across the loadspectrum. RJS variables also had high ICC except for time parameters for early force production. All variables were significantly (p < 0.01) related between LPT and force platform methods with no indication of systematic bias. The LPT appears to be a valid method of assessing force under these experimental conditions

Effect of a liquid multi-vitamin-mineral supplement on anaerobic exercise performance

This is the publisher's version, also found at http://ehis.ebscohost.com/ehost/detail?sid=10f44d64-ddff-470e-a85a-b4c63b016efa%40sessionmgr10&vid=1&hid=2&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#db=s3h&AN=20338872The purpose of this study was to determine if supplementation with a liquid multi-vitamin/mineral would improve anaerobic exercise performance. Fourteen resistance-trained men performed a 30-second cycle sprint and one set of squat exercise on 2 separate days before and following 8 weeks of supplementation with either a liquid multi-vitamin/ mineral or a placebo. Heart rate, perceived exertion, blood lactate, peak and mean power, and rate of fatigue were determined for all tests. No differences were noted for any variable (P > 0.05). When controlling for presupplementation values, however, a decreased rate of fatigue was noted for both exercise tests following the multi-vitamin/mineral supplementation. These data suggest that in resistance trained men consuming a nutritionally sound diet, supplementation with a liquid multi-vitamin/mineral does not favorably impact most anaerobic exercise performances. Such supplementation, however, may result in a minor decreased rate of fatigue. It appears that, in terms of improved short duration anaerobic exercise performance, supplemental micronutrients may not be efficient ergogenic agents for well-trained individuals consuming an adequate diet

Muscle fiber and performance adaptations to resistance exercise with MyoVive, colostrum or casein and whey supplementationa

This is the publisher's version, also found at http://ehis.ebscohost.com/ehost/detail?sid=ba69ee0d-97cf-4a2c-a1a2-2c26fb60d65c%40sessionmgr13&vid=1&hid=2&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#db=s3h&AN=10725638To determine the effects of 12 weeks of resistance exercise with MyoVive and/or colostrum supplementation, 19 male and female recreationally weighttrained subjects (X ± SE; age = 28.3 ± 6.9 yrs; hgt = 68.2 ± 3.8 cm) were divided into MyoVive + colostrum (n = 4), MyoVive + casein & whey (n = 4), colostrum + casein & whey (n = 6), and casein & whey (n = 5) groups. All groups similarly increased (p < .05) 1 repetition maximum (RM) leg press (kg; pre = 158.6 ± 12.8, post = 189.3 ± 11.3), body mass (kg; pre = 79.0 ± 3.2, post = 80.7 ± 3.8), and lean body mass (kg; pre = 60.1 ± 3.1, post = 62.2 ± 2.8). Increases were observed for peak force (N; all loads), peak velocity (m.s-1; 70% & 40% 1 RM), and peak power (W; 70% & 40% 1 RM) for all groups for the leg press exercise, with no differences between groups. When performance data were adjusted for body mass, lean body mass, lower body lean mass as determined by DEXA, or % change, no group differences were observed. Relative (%) fiber type content, cross-sectional areas (mm2), % fiber type areas, or % myosin heavy chain expression did not change for any group. These data suggest that MyoVive and colostrum supplementation have no greater effect on cellular and performance adaptations when compared to casein and whey protein

Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry

Background This study aimed to assess long-term safety and developmental data on juvenile idiopathic arthritis (JIA) patients treated in routine clinical practice with celecoxib or nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs). Methods Children aged ≥2 to \u3c18 years with rheumatoid-factor–positive or –negative polyarthritis, persistent or extended oligoarthritis, or systemic arthritis were enrolled into this prospective, observational, multicenter standard-of-care registry. Eligible patients were newly or recently prescribed (≤6 months) an nsNSAID or celecoxib. Enrolled patients were followed to the end of the study, whether they remained on the original NSAID, switched, or discontinued therapy altogether. All adverse events (AEs) regardless of severity were captured in the database. Results A total of 274 patients (nsNSAID, n = 219; celecoxib, n = 55) were observed for 410 patient-years of observation. Naproxen, meloxicam, and nabumetone were the most frequently used nsNSAIDs. At baseline, the celecoxib group was older, had a numerically longer median time since diagnosis, and a numerically higher proportion of patients with a history of gastrointestinal-related NSAID intolerance. AEs reported were those frequently observed with NSAID treatment and were similar across groups (nsNSAIDs: 52.0%; celecoxib: 52.9%). Twelve unique patients experienced a total of 18 serious AEs; the most frequent were infections, and none was attributed to NSAID use. Conclusions The safety profile of celecoxib and nsNSAIDs appears similar overall. The results from this registry, ongoing pharmacovigilance, and the phase 3 trial that led to the approval of celecoxib for children with JIA provide evidence that the benefit-risk for celecoxib treatment in JIA remains positive

Impact of socioeconomic deprivation on rate and cause of death in severe mental illness

Background: Socioeconomic status has important associations with disease-specific mortality in the general population. Although individuals with Severe Mental Illnesses (SMI) experience significant premature mortality, the relationship between socioeconomic status and mortality in this group remains under investigated.&lt;p&gt;&lt;/p&gt; Aims: To assess the impact of socioeconomic status on rate and cause of death in individuals with SMI (schizophrenia and bipolar disorder) relative to the local (Glasgow) and wider (Scottish) populations.&lt;p&gt;&lt;/p&gt; Methods: Cause and age of death during 2006-2010 inclusive for individuals with schizophrenia or bipolar disorder registered on the Glasgow Psychosis Clinical Information System (PsyCIS) were obtained by linkage to the Scottish General Register Office (GRO). Rate and cause of death by socioeconomic status, measured by Scottish Index of Multiple Deprivation (SIMD), were compared to the Glasgow and Scottish populations.&lt;p&gt;&lt;/p&gt; Results: Death rates were higher in people with SMI across all socioeconomic quintiles compared to the Glasgow and Scottish populations, and persisted when suicide was excluded. Differences were largest in the most deprived quintile (794.6 per 10,000 population vs. 274.7 and 252.4 for Glasgow and Scotland respectively). Cause of death varied by socioeconomic status. For those living in the most deprived quintile, higher drug-related deaths occurred in those with SMI compared to local Glasgow and wider Scottish population rates (12.3% vs. 5.9%, p = &#60;0.001 and 5.1% p = 0.002 respectively). A lower proportion of deaths due to cancer in those with SMI living in the most deprived quintile were also observed, relative to the local Glasgow and wider Scottish populations (12.3% vs. 25.1% p = 0.013 and 26.3% p = &#60;0.001). The proportion of suicides was significantly higher in those with SMI living in the more affluent quintiles relative to Glasgow and Scotland (54.6% vs. 5.8%, p = &#60;0.001 and 5.5%, p = &#60;0.001). Discussion and conclusions: Excess mortality in those with SMI occurred across all socioeconomic quintiles compared to the Glasgow and Scottish populations but was most marked in the most deprived quintiles when suicide was excluded as a cause of death. Further work assessing the impact of socioeconomic status on specific causes of premature mortality in SMI is needed

Communications Biophysics

Contains research objectives and reports on six research projects

Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry

BACKGROUND: This study aimed to assess long-term safety and developmental data on juvenile idiopathic arthritis (JIA) patients treated in routine clinical practice with celecoxib or nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs). METHODS: Children aged ≥2 to <18 years with rheumatoid-factor–positive or –negative polyarthritis, persistent or extended oligoarthritis, or systemic arthritis were enrolled into this prospective, observational, multicenter standard-of-care registry. Eligible patients were newly or recently prescribed (≤6 months) an nsNSAID or celecoxib. Enrolled patients were followed to the end of the study, whether they remained on the original NSAID, switched, or discontinued therapy altogether. All adverse events (AEs) regardless of severity were captured in the database. RESULTS: A total of 274 patients (nsNSAID, n = 219; celecoxib, n = 55) were observed for 410 patient-years of observation. Naproxen, meloxicam, and nabumetone were the most frequently used nsNSAIDs. At baseline, the celecoxib group was older, had a numerically longer median time since diagnosis, and a numerically higher proportion of patients with a history of gastrointestinal-related NSAID intolerance. AEs reported were those frequently observed with NSAID treatment and were similar across groups (nsNSAIDs: 52.0%; celecoxib: 52.9%). Twelve unique patients experienced a total of 18 serious AEs; the most frequent were infections, and none was attributed to NSAID use. CONCLUSIONS: The safety profile of celecoxib and nsNSAIDs appears similar overall. The results from this registry, ongoing pharmacovigilance, and the phase 3 trial that led to the approval of celecoxib for children with JIA provide evidence that the benefit-risk for celecoxib treatment in JIA remains positive. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00688545

Communications Biophysics

Contains research objectives and summary of research on five research projects, with ten sub-topics.National Institutes of Health (Grant 1 RO1 NS10916-01)National Institutes of Health (Grant 5 RO1 NS11000-03)National Institutes of Health (Grant 1 RO1 NS11153-01)Harvard-M.I.T. Rehabilitation Engineering CenterU. S. Department of Health, Education, and Welfare (Grant 23-P-55854)National Institutes of Health (Grant 1 RO1 NS11680-01)National Institutes of Health (Grant 5 ROI NS11080-02)M.I.T. Health Sciences FundNational Aeronautics and Space Administration (Grant NSG-2032)National Institutes of Health (Grant 5 TO1 GM01555-09)Massachusetts General Hospital Purchase Order F63853Boston City Hospital Purchase Order 4338-7543

Communications Biophysics

Contains research objectives, summary of research and reports on two research projects.National Institutes of Health (Grant 5 PO1 GM-14940-02)Joint Services Electronics Programs (U. S. Army, U.S. Navy, and U. S. Air Force) under Contract DA 28-043-AMC-02536(E)National Aeronautics and Space Administration (Grant NGL 22-009-304)National Institutes of Health (Grant 5 TO1 GM-01555-02)National Institutes of Health (Grant NB-08082-01